Leucine-rich repeat kinase 2 (LRRK2) is a multifunctional protein that orchestrates a diverse
array of cellular processes, including vesicle transport, autophagy, lysosome degradation …

Nanobodies are antibody fragments derived from camelids, naturally endowed with
properties like low molecular weight, high affinity and low immunogenicity, which contribute …

LRRK2 is one of the most promising drug targets for Parkinson's disease. Though type I
kinase inhibitors of LRRK2 are under clinical trials, alternative strategies like type II inhibitors …

Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common causes of
Parkinson's disease (PD) to date. Dysfunction in LRRK2 enzymatic activities and elevated …

Missense variants in leucine-rich repeat kinase 2 (LRRK2) lead to familial and sporadic
Parkinson's disease (PD). The pathological features of PD patients with LRRK2 variants …

Treatments for central nervous system diseases with therapeutic antibodies have been
increasingly investigated over the last decades, leading to some approved monoclonal …

Understanding the pathophysiology and genetic background of Parkinson's disease (PD)
increases the likelihood of developing effective disease-modifying therapeutic strategies. In …

Heavy‐chain antibodies (HCAbs) are a unique type of antibodies devoid of light chains, and
comprised of two heavy chains‐only that recognize their cognate antigen by virtue of a …

Nanobodies (Nbs) are antibody fragments derived from heavy-chain-only IgG antibodies
found in the Camelidae family as well as cartilaginous fish. Their unique structural and …

In this work, we report the development of a platform for the early selection of non-
competitive antibody-fragments against cell surface receptors that do not compete for …